Rapid in vivo screening of tumor-targeting aptamers using zebrafish larvae
4 affiliations
- 1Department of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
- 2Department of Surgery, Mayo Clinic, Rochester, MN, USA
- 3Department of Transplantation, Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL 32224, USA
- 4Department of Molecular Pharmacology and Experimental Therapeutics, Center for Individualized Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Abstract
Although in vitro methods for aptamer screening are well established, quantitative systematic in vivo screening of multiple aptamers remains challenging due to time and cost constraints associated with rodent models. To address this bottleneck, we developed a strategy for rapid screening of tumor-targeting aptamers using light-sheet fluorescent imaging after systemic administration of aptamers in a zebrafish larvae neuroblastoma model. Correlated imaging and qPCR-based aptamer detection identified an optimal screening window of 30–90 min post-injection, enabling rapid in vivo evaluation of five aptamers and one negative control oligonucleotide. We compared this strategy with in vitro screening of the same aptamers against a panel of neuroblastoma cell lines and found that zebrafish larvae screening ranked lead aptamers differently from in vitro assays, suggesting that in vivo screening may identify more physiological tumor-preferential aptamers for therapeutic development than in vitro screening alone. To demonstrate the therapeutic potential, the lead aptamer was conjugated to fusogenic nanovesicles and showed reproducible neuroblastoma-preferential accumulation 1–2 h post-injection. This strategy enables rapid in vivo evaluation of aptamers selected in vitro to identify candidates with tumor-targeting properties. Importantly, this in vivo approach can also assess off-target binding to healthy tissues without the time and cost associated with rodent models.
Related
- Selection and characterization of ssDNA aptamers targeting tick-borne encephalitis virus particles
- Selection of DNA aptamers targeting PirAB toxin for potential biosensing applications in acute hepatopancreatic necrosis disease (AHPND)
- Computationally Guided Design and Experimental Validation of ssDNA Aptamers Targeting the SARS-CoV-2 Spike Protein
- Rapid screening of ancient DNA extracts through uracil detection
- A Cell-based Screening Method Using an Intracellular Antibody for Discovering Small Molecules Targeting Hard-to-drug Proteins
BibTeX
@article{schaefer2026rapid,
title = {{Rapid in vivo screening of tumor-targeting aptamers using zebrafish larvae}},
author = {Madison A. Schaefer and Brandon Wilbanks and Irene K. Yan and Alexis M. Sosic and Julia Driscoll and Rory L. Smoot and Tushar Patel and L. James Maher and Shizhen Zhu},
journal = {Molecular Therapy. Nucleic Acids},
year = {2026},
month = sep,
doi = {10.1016/j.omtn.2026.103119},
url = {https://doi.org/10.1016/j.omtn.2026.103119},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Rapid in vivo screening of tumor-targeting aptamers using zebrafish larvae
AU - Madison A. Schaefer
AU - Brandon Wilbanks
AU - Irene K. Yan
AU - Alexis M. Sosic
AU - Julia Driscoll
AU - Rory L. Smoot
AU - Tushar Patel
AU - L. James Maher
AU - Shizhen Zhu
PY - 2026
DA - 2026/09/29
JO - Molecular Therapy. Nucleic Acids
DO - 10.1016/j.omtn.2026.103119
UR - https://doi.org/10.1016/j.omtn.2026.103119
AB - Although in vitro methods for aptamer screening are well established, quantitative systematic in vivo screening of multiple aptamers remains challenging due to time and cost constraints associated with rodent models. To address this bottleneck, we developed a strategy for rapid screening of tumor-targeting aptamers using light-sheet fluorescent imaging after systemic administration of aptamers in a zebrafish larvae neuroblastoma model. Correlated imaging and qPCR-based aptamer detection identified an optimal screening window of 30–90 min post-injection, enabling rapid in vivo evaluation of five aptamers and one negative control oligonucleotide. We compared this strategy with in vitro screening of the same aptamers against a panel of neuroblastoma cell lines and found that zebrafish larvae screening ranked lead aptamers differently from in vitro assays, suggesting that in vivo screening may identify more physiological tumor-preferential aptamers for therapeutic development than in vitro screening alone. To demonstrate the therapeutic potential, the lead aptamer was conjugated to fusogenic nanovesicles and showed reproducible neuroblastoma-preferential accumulation 1–2 h post-injection. This strategy enables rapid in vivo evaluation of aptamers selected in vitro to identify candidates with tumor-targeting properties. Importantly, this in vivo approach can also assess off-target binding to healthy tissues without the time and cost associated with rodent models.
SN - 2162-2531
ER -